Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma reported Q1 2023 financial results and business updates. Key highlights include:
- YUPELRI net sales of $47.0 million, up 8% year-over-year
- YUPELRI retail new patient starts and total prescriptions up 61% and 29% respectively, reaching all-time highs
- CYPRESS Phase 3 study of ampreloxetine actively recruiting
- On track to complete $325 million capital return program by year-end; $215 million of share repurchases completed through 4/30/23
- Q1 2023 total revenue was $10.4 million, primarily from Viatris collaboration
- Net loss from continuing operations was $22.1 million in Q1 2023
- Cash, cash equivalents and marketable securities totaled $260.0 million as of March 31, 2023
The company expects full year 2023 R&D expense of $35-45 million and SG&A expense of $45-55 million, and anticipates generating non-GAAP profit in 2H 2023.
Theravance Biopharma (NASDAQ: TBPH) is set to announce its first quarter 2023 financial results on May 8, 2023, after market close. The announcement will be followed by a conference call at 5:00 pm ET, providing insights into the company’s business developments and performance metrics. Following the call, a replay will be accessible for 30 days until June 7, 2023. The company focuses on delivering innovative treatments, including its FDA-approved medication for COPD and a late-stage investigational drug for neurogenic orthostatic hypotension. The aim is to enhance shareholder value through its continuous development efforts.
Irenic Capital Management, a significant shareholder of Theravance Biopharma (NASDAQ: TBPH), expressed support for the recent appointment of Jim Kelly to the Board of Directors. Irenic believes Kelly will provide a key shareholder perspective that is essential for the boardroom. The firm commended Theravance for its efforts to enhance capital allocation, including expanding the capital return program and a proposal to declassify the Board. Irenic urged the Board to take further steps, such as reviewing strategic alternatives, accelerating the capital return program, and ensuring directors are elected on a one-year term. The emphasis remains on improving governance and value creation for shareholders.
